Equities

Raphael Pharmaceutical Inc

RAPH:QBB

Raphael Pharmaceutical Inc

Actions
  • Price (USD)1.00
  • Today's Change0.00 / 0.00%
  • Shares traded350.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Dec 20 2023 14:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Raphael Pharmaceutical Inc. is a pharmaceutical drug research and development company. The Company is focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol (CBD) oil. The Company is in pre-clinical development stage for its lead product candidate, rheumatoid arthritis (RA), for the treatment of RA. In addition, the Company is also developing a pharmaceutical drug product for the treatment of hyperinflammatory syndrome inflammation related to COVID-19. The Company’s discovery platform focuses the use of CBD oil, one of the cannabinoids in cannabis plants, as the active pharmaceutical ingredient (API), for its RA product candidate and COVID-19 product candidate.

  • Revenue in USD (TTM)0.00
  • Net income in USD-1.28m
  • Incorporated2007
  • Employees0.00
  • Location
    Raphael Pharmaceutical IncSUITE 105 - 5348 VEGAS DR.LAS VEGAS 89108United StatesUSA
  • Phone+1 (702) 442-1166
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pharmacyte Biotech Inc0.00-14.82m17.67m2.00--0.5676-----1.64-1.640.005.740.00----0.00-1.53-13.35-1.62-13.70------------0.00-------1.81------
Plus Therapeutics Inc (USA)4.91m-13.32m17.70m20.00------3.60-4.51-4.511.57-0.30330.2787----245,650.00-75.54-59.18-210.10-133.04-----271.04-470.45----1.51--2,093.30-5.8934.32--3.77--
Minerva Neurosciences Inc0.00-31.60m17.96m9.00---------4.48-4.480.00-5.230.00----0.00-61.90-49.89-65.32-52.39-------442.65------------6.55------
Cardio Diagnostics Holdings Inc17.07k-8.38m18.11m7.00--5.83--1,061.22-0.7363-0.73630.00140.1440.0032--6.882,438.57-156.40---211.46-------49,073.46-----5.450.1122--1,696.84---79.72------
GlycoMimetics Inc10.00k-37.28m18.12m35.00--0.6267--1,811.70-0.5791-0.57910.00020.44860.0002--0.0581285.71-72.29-43.60-81.84-47.82-----372,767.40-2,243.52----0.00---86.67--20.97---29.82--
Biomx Inc0.00-26.17m18.23m58.00--4.93-----0.5433-0.54330.000.0670.00----0.00-74.18---101.74-------------21.950.7841------7.59------
VBI Vaccines Inc9.41m-83.99m18.63m131.00------1.98-6.93-6.930.4818-0.21660.09231.4037.0571,839.70-81.40-46.58-171.57-58.62-24.06-277.46-881.79-2,755.980.2116-1.601.13--702.4020.9417.18---32.07--
Raphael Pharmaceutical Inc0.00-1.28m18.66m0.00--69.30-----0.0799-0.07990.000.01440.00-------382.14---688.47-------------106.000.1246------61.76------
KALA BIO Inc0.00-39.55m18.95m43.00--2.85-----15.15-15.150.002.370.00----0.00-63.15-57.83-76.71-69.32--57.06---1,553.61---12.260.8382---100.00--5.85---17.31--
MEI Pharma Inc66.75m26.16m19.52m46.000.74640.38260.73640.29253.933.9310.027.660.6498--29.151,451,174.0025.46-25.3130.38-28.59----39.18-122.05----0.00--19.9597.5641.53------
Synlogic Inc3.21m-73.22m19.53m6.00--1.47--6.09-10.62-10.620.45761.150.0495----534,166.70-113.09-40.57-134.57-43.82-----2,284.68-3,245.93----0.00008--185.685.9913.40---48.05--
Alaunos Therapeutics Inc6.00k-26.77m19.54m1.00--4.07--3,255.87-1.67-1.670.00040.29960.0002--12.006,000.00-97.94-74.83-147.22-89.57-----446,233.30-10,508.06---19.250.00---99.83-49.086.86---15.56--
Talphera Inc651.00k-14.31m19.54m15.00--1.20--30.02-0.8945-0.88630.03680.96120.0237----43,400.00-51.96-22.60-67.70-28.55-----2,197.39-714.87----0.00-----21.26-119.16---34.33--
Goldenwell Biotech Inc2.34k-116.90k19.80m----233.71--8,461.54-0.0012-0.00120.000020.00090.00980.0071-----49.07---52.16--47.01---4,995.73--37.75--0.00---95.10--88.13------
Data as of Dec 20 2023. Currency figures normalised to Raphael Pharmaceutical Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.